Stay updated on Guselkumab in Active PsA: Efficacy & Safety Clinical Trial
Sign up to get notified when there's something new on the Guselkumab in Active PsA: Efficacy & Safety Clinical Trial page.

Latest updates to the Guselkumab in Active PsA: Efficacy & Safety Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal regarding the study of guselkumab for Psoriatic Arthritis, including detailed descriptions of the study's purpose, methodology, and eligibility criteria. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference8%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 4, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 4, 2025, and version 2.14.2.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.4%
- Check87 days agoChange DetectedThe webpage has been updated to reflect new dates and locations, specifically changing from Poznań, Poland to Poznan, Poland, and updating the last update dates to early 2025. Additionally, there is a notice regarding heavy traffic affecting NLM-NCBI services.SummaryDifference0.7%
Stay in the know with updates to Guselkumab in Active PsA: Efficacy & Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guselkumab in Active PsA: Efficacy & Safety Clinical Trial page.